Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q3 2026, worth $8.77M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 17, 2026, 2:22 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 30, 2026 | Feb 27, 2025 | Mar 4, 2024 | Mar 8, 2023 | Mar 18, 2022 |
| Cost of revenue | $41.6M | – | – | – | – |
| Operating expenses | $83.9M | $76.2M | $68.9M | $51.2M | $36.8M |
| Research and development | $63.1M | $55.8M | $51.8M | $34.6M | $25.4M |
| Selling, general and administrative | $20.8M | $20.4M | $17.1M | $16.6M | $11.4M |
| Operating income | -$83.9M | -$76.2M | -$68.9M | -$51.2M | -$36.8M |
| Income tax | – | $2.00K | – | – | – |
| Net income | -$75.8M | -$71.3M | -$64.5M | -$37.7M | -$30.6M |
| EPS, basic | $-3.95 | $-4.89 | $-6.18 | $-1.03 | – |
| EPS, diluted | $-3.95 | $-4.89 | $-6.18 | $-1.03 | – |
| Weighted shares, basic | 19.2M | 14.6M | 10.4M | 36.5M | – |
| Weighted shares, diluted | 19.2M | 14.6M | 10.4M | 36.5M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 30, 2026 | Feb 27, 2025 | Mar 4, 2024 | Mar 8, 2023 | Mar 18, 2022 |
| Cash and equivalents | $28.7M | $71.6M | $86.9M | $38.3M | $84.7M |
| Total current assets | $34.6M | $75.8M | $88.9M | $41.7M | $87.8M |
| Property, plant and equipment | $102.0K | $1.88M | $2.73M | $3.57M | $3.69M |
| Total assets | $35.8M | $79.9M | $94.9M | $48.4M | $93.7M |
| Accounts payable | $6.22M | $4.03M | $4.15M | $1.77M | $3.92M |
| Total current liabilities | $13.2M | $15.2M | $12.4M | $7.07M | $8.02M |
| Total liabilities | $31.6M | $18.2M | $16.5M | $12.4M | $24.1M |
| Shareholders' equity | $4.15M | $61.7M | $78.4M | $36.0M | $69.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 30, 2026 | Feb 27, 2025 | Mar 4, 2024 | Mar 8, 2023 | Mar 18, 2022 |
| Operating cash flow | -$77.2M | -$62.6M | -$52.1M | -$45.9M | -$33.7M |
| Depreciation and amortization | $1.06M | $1.37M | $1.11M | $975.0K | $377.0K |
| Stock-based compensation | $6.71M | $6.62M | $5.21M | $4.09M | $1.05M |
| Investing cash flow | $5.00K | -$532.0K | -$267.0K | -$576.0K | -$2.43M |
| Financing cash flow | $34.2M | $47.9M | $101.0M | $55.0K | $101.0M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.